Phathom Pharmaceuticals Statistics
Share Statistics
Phathom Pharmaceuticals has 69.81M
shares outstanding. The number of shares has increased by 18.97%
in one year.
Shares Outstanding | 69.81M |
Shares Change (YoY) | 18.97% |
Shares Change (QoQ) | 1.84% |
Owned by Institutions (%) | 99.99% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 28 |
FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 11.38M, so 16.35% of the outstanding
shares have been sold short.
Short Interest | 11.38M |
Short % of Shares Out | 16.35% |
Short % of Float | 27.32% |
Short Ratio (days to cover) | 8.37 |
Valuation Ratios
The PE ratio is -1.53 and the forward
PE ratio is -1.31.
Phathom Pharmaceuticals's PEG ratio is
-0.04.
PE Ratio | -1.53 |
Forward PE | -1.31 |
PS Ratio | 9.28 |
Forward PS | 0.2 |
PB Ratio | -2.02 |
P/FCF Ratio | -1.92 |
PEG Ratio | -0.04 |
Financial Ratio History Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Phathom Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.2,
with a Debt / Equity ratio of -0.8.
Current Ratio | 4.2 |
Quick Ratio | 4.16 |
Debt / Equity | -0.8 |
Debt / EBITDA | -0.77 |
Debt / FCF | -0.76 |
Interest Coverage | -3.85 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $129,395.78 |
Profits Per Employee | $-782,964.87 |
Employee Count | 427 |
Asset Turnover | 0.15 |
Inventory Turnover | 2.49 |
Taxes
Income Tax | n/a |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -77.5% in the
last 52 weeks. The beta is 0.15, so Phathom Pharmaceuticals's
price volatility has been higher than the market average.
Beta | 0.15 |
52-Week Price Change | -77.5% |
50-Day Moving Average | 4.78 |
200-Day Moving Average | 9.97 |
Relative Strength Index (RSI) | 25.18 |
Average Volume (20 Days) | 1,386,316 |
Income Statement
In the last 12 months, Phathom Pharmaceuticals had revenue of 55.25M
and earned -334.33M
in profits. Earnings per share was -5.29.
Revenue | 55.25M |
Gross Profit | 47.28M |
Operating Income | -277.47M |
Net Income | -334.33M |
EBITDA | -261.52M |
EBIT | -262.32M |
Earnings Per Share (EPS) | -5.29 |
Full Income Statement Balance Sheet
The company has 297.26M in cash and 201.91M in
debt, giving a net cash position of 95.35M.
Cash & Cash Equivalents | 297.26M |
Total Debt | 201.91M |
Net Cash | 95.35M |
Retained Earnings | -1.26B |
Total Assets | 378.32M |
Working Capital | 274.41M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -266.77M
and capital expenditures 0, giving a free cash flow of -266.9M.
Operating Cash Flow | -266.77M |
Capital Expenditures | n/a |
Free Cash Flow | -266.9M |
FCF Per Share | -4.22 |
Full Cash Flow Statement Margins
Gross margin is 85.57%, with operating and profit margins of -502.18% and -605.09%.
Gross Margin | 85.57% |
Operating Margin | -502.18% |
Pretax Margin | -605.09% |
Profit Margin | -605.09% |
EBITDA Margin | -473.33% |
EBIT Margin | -502.18% |
FCF Margin | -483.07% |